Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$70.49
$0.15(0.17%)
At close: 4:00 PM EDT
$70.49
$0.15(0.17%)
Day’s Range― - ―
52-Week Range$21.15 - $93.61
Previous CloseN/A
Volume722.63K
Average Volume (3M)1.42M
Market Cap
$6.15B
Enterprise Value$7.98K
Total Cash (Recent Filing)$284.18M
Total Debt (Recent Filing)$128.94M
Price to Earnings (P/E)43.8
Beta1.54
Next Earnings
Nov 10, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding89,508,890
10 Day Avg. Volume1,012,562
30 Day Avg. Volume1,421,259
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$106.71Price Target Upside51.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)3.07
Revenue Forecast (FY)$739.43M
Bulls Say, Bears Say
Bulls Say
Rapid YUTREPIA Commercial AdoptionRapid sales growth, patient starts, and prescriber adoption indicate that YUTREPIA is gaining meaningful traction in its target market. Continued penetration can support recurring product revenue, strengthen Liquidia’s commercial platform, and provide a foundation for expanding the franchise.
Strong Profitability And Cash BuildThe shift from years of losses to substantial revenue, high gross margins, and positive earnings demonstrates operating leverage as commercialization scales. Stronger cash generation gives Liquidia greater capacity to fund clinical programs, expand selling infrastructure, and absorb investment without relying solely on external capital.
Potential Expansion Of The Treprostinil FranchiseFast Track and the planned RE-WARM study extend YUTREPIA beyond pulmonary hypertension into a distinct rare-disease opportunity with stated unmet need. Although approval is not assured, successful development could diversify future revenue, expand the addressable market, and deepen the value of Liquidia’s platform.
Bears Say
Current Product Requires Four-times-daily DosingA four-times-daily regimen may reduce convenience and persistence for some patients, creating a lasting commercial hurdle even with strong initial uptake. Liquidia’s response depends partly on L606 development and execution, so the current product’s dosing burden may limit broader adoption before a lower-frequency option is available.
Planned Sharp Increase In Operating ExpensesHigher R&D and SG&A spending is intended to support commercialization and the pipeline, but it raises the cost base materially over the next several quarters. If product growth or clinical progress falls short of expectations, the planned investment could pressure margins, cash conversion, and the durability of current profitability.
Unresolved Patent Litigation ExposureOngoing patent litigation creates uncertainty around the economics and operating freedom of Liquidia’s commercial business. An unfavorable ruling could require royalties or other remedies, reducing product profitability and cash available for development while also complicating long-term planning for YUTREPIA.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $21.14 and its highest was $93.61 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $6.15B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Nov 10, 2026 which is in 64 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Aug 12, 2026. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.758 by -$0.018.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.88.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 89,508,890 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.74 in its last earnings report, missing expectations of $0.758. Following the earnings report the stock price went down -10.517%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$106.71 (51.39% Upside)
$106.71 (51.39% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 86%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 285.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $120.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
102.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Liquidia Technologies Inc
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum—robust quarter-over-quarter sales (+31%), substantial patient adoption (~5,000+ patients started) and improving profitability (net income ~$74.7M, adjusted EBITDA ~$96.3M) alongside a healthy cash build (~$284M). Clinical data and a progressing pipeline (10 studies, L606 Phase III enrollment) underpin future growth potential. Offsetting factors include a 4x daily dosing requirement for the current product, planned increases in R&D and SG&A (R&D expected to double in H2 2026), pending patent litigation that could create legal/royalty risk, and the need for further community penetration. On balance, the positive operational, financial, and clinical developments materially outweigh the manageable near-term risks.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$106.71
▲(51.39% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
30.14% Insiders
8.40% Mutual Funds
37.54% Other Institutional Investors
5.60% Public Companies and Individual Investors